Tech Company Financing Transactions
Adicet Bio Funding Round
On 10/4/2019, Adicet Bio secured $80 million in Series B funding from aMoon Partners, Consensus Business Group and DSC Investment.
Transaction Overview
Company Name
Announced On
10/4/2019
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series B
Investors
Proceeds Purpose
This financing will permit Adicet to continue to develop our proprietary technology, to enter the clinic in Non-Hodgkin's Lymphoma and to advance our solid tumor programs. We are gratified with the support of the investment community.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
200 Constitution Dr.
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Undisclosed
Website
Email Address
Overview
Adicet Bio, Inc. is a biotechnology company engaged in the design and development of cutting-edge immunotherapies for cancer and other disease indications, with a focus on novel universal immune cell therapies (uICT).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Donald Santel
Chief Executive Officer
Anil Singhal
Chief Financial Officer
Brian Hogan
Chief Medical Officer
Francesco Galimi
Chief Operating Officer
Stewart Abbot
Founder
Aya Jakobovits
VP - Human Resources
Carrie Krehlik
Browse more venture capital transactions:
Prev: 10/4/2019: BiomeSense venture capital transaction
Next: 10/4/2019: CoLab Software venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs